Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 218

1.

Feasibility and efficacy of addition of individualized-dose lenalidomide to chlorambucil and rituximab as first-line treatment in elderly and FCR-unfit patients with advanced chronic lymphocytic leukemia.

Kater AP, van Oers MHJ, van Norden Y, van der Straten L, Driessen J, Posthuma WFM, Schipperus M, Chamuleau MED, Nijland M, Doorduijn JK, Van Gelder M, Hoogendoorn M, De Croon F, Wittebol S, Kerst JM, Marijt EWA, Raymakers RAP, Schaafsma MR, Dobber JA, Kersting S, Levin MD; HOVON CLL study group.

Haematologica. 2019 Jan;104(1):147-154. doi: 10.3324/haematol.2018.193854. Epub 2018 Aug 16.

2.

Clonal diversity predicts adverse outcome in chronic lymphocytic leukemia.

Leeksma AC, Taylor J, Wu B, Gardner JR, He J, Nahas M, Gonen M, Alemayehu WG, Te Raa D, Walther T, Hüllein J, Dietrich S, Claus R, de Boer F, de Heer K, Dubois J, Dampmann M, Dürig J, van Oers MHJ, Geisler CH, Eldering E, Levine RL, Miller V, Mughal T, Lamanna N, Frattini MG, Heaney ML, Zelenetz A, Zenz T, Abdel-Wahab O, Kater AP.

Leukemia. 2019 Feb;33(2):390-402. doi: 10.1038/s41375-018-0215-9. Epub 2018 Jul 23.

3.

Profiling of volatile organic compounds produced by clinical Aspergillus isolates using gas chromatography-mass spectrometry.

Gerritsen MG, Brinkman P, Escobar N, Bos LD, de Heer K, Meijer M, Janssen HG, de Cock H, Wösten HAB, Visser CE, van Oers MHJ, Sterk PJ.

Med Mycol. 2018 Feb 1;56(2):253-256. doi: 10.1093/mmy/myx035.

PMID:
28525576
4.

International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017).

Younes A, Hilden P, Coiffier B, Hagenbeek A, Salles G, Wilson W, Seymour JF, Kelly K, Gribben J, Pfreunschuh M, Morschhauser F, Schoder H, Zelenetz AD, Rademaker J, Advani R, Valente N, Fortpied C, Witzig TE, Sehn LH, Engert A, Fisher RI, Zinzani PL, Federico M, Hutchings M, Bollard C, Trneny M, Elsayed YA, Tobinai K, Abramson JS, Fowler N, Goy A, Smith M, Ansell S, Kuruvilla J, Dreyling M, Thieblemont C, Little RF, Aurer I, Van Oers MHJ, Takeshita K, Gopal A, Rule S, de Vos S, Kloos I, Kaminski MS, Meignan M, Schwartz LH, Leonard JP, Schuster SJ, Seshan VE.

Ann Oncol. 2017 Jul 1;28(7):1436-1447. doi: 10.1093/annonc/mdx097. Review.

5.

Rituximab maintenance improves overall survival of patients with follicular lymphoma-Individual patient data meta-analysis.

Vidal L, Gafter-Gvili A, Salles G, Bousseta S, Oberman B, Rubin C, van Oers MH, Fortpied C, Ghielmini M, Pettengell R, Witzens-Harig M, Dreger P, Vitolo U, Gomes da Silva M, Evangelista A, Li H, Freedman L, Habermann TM, Shpilberg O.

Eur J Cancer. 2017 May;76:216-225. doi: 10.1016/j.ejca.2017.01.021. Epub 2017 Mar 21.

PMID:
28336303
6.

Soluble CD52 is an indicator of disease activity in chronic lymphocytic leukemia.

Vojdeman FJ, Herman SEM, Kirkby N, Wiestner A, van T' Veer MB, Tjønnfjord GE, Itälä-Remes MA, Kimby E, Farooqui MZ, Polliack A, Wu KL, Doorduijn JK, Alemayehu WG, Wittebol S, Kozak T, Walewski J, Abrahamse-Testroote MCJ, van Oers MHJ, Geisler CH, Niemann CU.

Leuk Lymphoma. 2017 Oct;58(10):2356-2362. doi: 10.1080/10428194.2017.1285027. Epub 2017 Feb 7.

7.

The pan phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor SAR245409 (voxtalisib/XL765) blocks survival, adhesion and proliferation of primary chronic lymphocytic leukemia cells.

Thijssen R, Ter Burg J, van Bochove GG, de Rooij MF, Kuil A, Jansen MH, Kuijpers TW, Baars JW, Virone-Oddos A, Spaargaren M, Egile C, van Oers MH, Eldering E, Kersten MJ, Kater AP.

Leukemia. 2016 Sep;30(9):1963. doi: 10.1038/leu.2016.184. No abstract available.

PMID:
27600169
8.

The HOVON68 CLL trial revisited: performance status and comorbidity affect survival in elderly patients with chronic lymphocytic leukemia.

Vojdeman FJ, Van't Veer MB, Tjønnfjord GE, Itälä-Remes M, Kimby E, Polliack A, Wu KL, Doorduijn JK, Alemayehu WG, Wittebol S, Kozak T, Walewski J, Abrahamse-Testroote MC, van Oers MH, Geisler CH.

Leuk Lymphoma. 2017 Mar;58(3):594-600. doi: 10.1080/10428194.2016.1213831. Epub 2016 Aug 2. Erratum in: Leuk Lymphoma. 2017 Mar;58(3):758.

PMID:
27484290
9.

eNose technology can detect and classify human pathogenic molds in vitro: a proof-of-concept study of Aspergillus fumigatus and Rhizopus oryzae.

de Heer K, Vonk SI, Kok M, Kolader M, Zwinderman AH, van Oers MH, Sterk PJ, Visser CE.

J Breath Res. 2016 Jul 22;10(3):036008. doi: 10.1088/1752-7155/10/3/036008.

PMID:
27447026
10.

Correction for de Heer et al., Detection of Airway Colonization by Aspergillus fumigatus by Use of Electronic Nose Technology in Patients with Cystic Fibrosis.

de Heer K, Kok MGM, Fens N, Weersink EJM, Zwinderman AH, van der Schee MPC, Visser CE, van Oers MHJ, Sterk PJ.

J Clin Microbiol. 2016 Jul;54(7):1926. doi: 10.1128/JCM.00748-16. No abstract available.

11.

Analysis of prognosis in CLL: collaboration makes the difference.

van Oers MHJ.

Lancet Oncol. 2016 Jun;17(6):691-692. doi: 10.1016/S1470-2045(16)30052-3. Epub 2016 May 13. No abstract available.

PMID:
27185641
12.

Efficacy of cisplatin-based immunochemotherapy plus alloSCT in high-risk chronic lymphocytic leukemia: final results of a prospective multicenter phase 2 HOVON study.

van Gelder M, van Oers MH, Alemayehu WG, Abrahamse-Testroote MC, Cornelissen JJ, Chamuleau ME, Zachée P, Hoogendoorn M, Nijland M, Petersen EJ, Beeker A, Timmers GJ, Verdonck L, Westerman M, de Weerdt O, Kater AP.

Bone Marrow Transplant. 2016 Jun;51(6):799-806. doi: 10.1038/bmt.2016.9. Epub 2016 Feb 15.

PMID:
26878656
13.

Rituximab and risk of second primary malignancies in patients with non-Hodgkin lymphoma: a systematic review and meta-analysis.

Fleury I, Chevret S, Pfreundschuh M, Salles G, Coiffier B, van Oers MH, Gisselbrecht C, Zucca E, Herold M, Ghielmini M, Thieblemont C.

Ann Oncol. 2016 Mar;27(3):390-7. doi: 10.1093/annonc/mdv616. Epub 2015 Dec 17. Review.

PMID:
26681685
14.

Detection of Airway Colonization by Aspergillus fumigatus by Use of Electronic Nose Technology in Patients with Cystic Fibrosis.

de Heer K, Kok MG, Fens N, Weersink EJ, Zwinderman AH, van der Schee MP, Visser CE, van Oers MH, Sterk PJ.

J Clin Microbiol. 2016 Mar;54(3):569-75. doi: 10.1128/JCM.02214-15. Epub 2015 Dec 16. Erratum in: J Clin Microbiol. 2016 Jul;54(7):1926.

15.

Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study.

van Oers MH, Kuliczkowski K, Smolej L, Petrini M, Offner F, Grosicki S, Levin MD, Gupta I, Phillips J, Williams V, Manson S, Lisby S, Geisler C; PROLONG study investigators.

Lancet Oncol. 2015 Oct;16(13):1370-9. doi: 10.1016/S1470-2045(15)00143-6. Epub 2015 Sep 13.

PMID:
26377300
16.

The pan phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor SAR245409 (voxtalisib/XL765) blocks survival, adhesion and proliferation of primary chronic lymphocytic leukemia cells.

Thijssen R, Ter Burg J, van Bochove GG, de Rooij MF, Kuil A, Jansen MH, Kuijpers TW, Baars JW, Virone-Oddos A, Spaargaren M, Egile C, van Oers MH, Eldering E, Kersten MJ, Kater AP.

Leukemia. 2016 Feb;30(2):337-45. doi: 10.1038/leu.2015.241. Epub 2015 Sep 4. Erratum in: Leukemia. 2016 Sep;30(9):1963.

PMID:
26338274
17.

Assessment of p53 and ATM functionality in chronic lymphocytic leukemia by multiplex ligation-dependent probe amplification.

te Raa GD, Moerland PD, Leeksma AC, Derks IA, Yigittop H, Laddach N, Loden-van Straaten M, Navrkalova V, Trbusek M, Luijks DM, Zenz T, Skowronska A, Hoogendoorn M, Stankovic T, van Oers MH, Eldering E, Kater AP.

Cell Death Dis. 2015 Aug 6;6:e1852. doi: 10.1038/cddis.2015.223.

18.

Quality of life of patients with chronic lymphocytic leukaemia in the Netherlands: results of a longitudinal multicentre study.

Holtzer-Goor KM, Schaafsma MR, Joosten P, Posthuma EF, Wittebol S, Huijgens PC, Mattijssen EJ, Vreugdenhil G, Visser H, Peters WG, Erjavec Z, Wijermans PW, Daenen SM, van der Hem KG, van Oers MH, Uyl-de Groot CA.

Qual Life Res. 2015 Dec;24(12):2895-906. doi: 10.1007/s11136-015-1039-y. Epub 2015 Jul 24.

19.

Resistance to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors.

Thijssen R, Slinger E, Weller K, Geest CR, Beaumont T, van Oers MH, Kater AP, Eldering E.

Haematologica. 2015 Aug;100(8):e302-6. doi: 10.3324/haematol.2015.124560. Epub 2015 May 8. No abstract available.

20.

Extended follow up of high-dose melphalan and autologous stem cell transplantation after vincristine, doxorubicin, dexamethasone induction in amyloid light chain amyloidosis of the prospective phase II HOVON-41 study by the Dutch-Belgian Co-operative Trial Group for Hematology Oncology.

Hazenberg BP, Croockewit A, van der Holt B, Zweegman S, Bos GM, Delforge M, Raymakers RA, Sonneveld P, Vellenga E, Wijermans PW, von dem Borne PA, van Oers MH, de Weerdt O, Spoelstra FM, Lokhorst HM; Dutch-Belgian Cooperative Trial Group for Hematology Oncology.

Haematologica. 2015 May;100(5):677-82. doi: 10.3324/haematol.2014.119198. Epub 2015 Feb 6.

21.

Induction of TAp73 by platinum-based compounds to overcome drug resistance in p53 dysfunctional chronic lymphocytic leukemia.

Tonino SH, Mulkens CE, van Laar J, Derks IA, Suo G, Croon-de Boer F, van Oers MH, Eldering E, Wang JY, Kater AP.

Leuk Lymphoma. 2015;56(8):2439-47. doi: 10.3109/10428194.2014.996751. Epub 2015 Jan 21.

22.

The impact of SF3B1 mutations in CLL on the DNA-damage response.

Te Raa GD, Derks IA, Navrkalova V, Skowronska A, Moerland PD, van Laar J, Oldreive C, Monsuur H, Trbusek M, Malcikova J, Lodén M, Geisler CH, Hüllein J, Jethwa A, Zenz T, Pospisilova S, Stankovic T, van Oers MH, Kater AP, Eldering E.

Leukemia. 2015 May;29(5):1133-42. doi: 10.1038/leu.2014.318. Epub 2014 Nov 5.

PMID:
25371178
23.

Early discharge after high dose chemotherapy is safe and feasible: a prospective evaluation of 6 years of home care.

Mank AP, Schoonenberg C, Bleeker K, Heijmenberg S, Heer Kd, van Oers MH, Kersten MJ.

Leuk Lymphoma. 2015 Jul;56(7):2098-104. doi: 10.3109/10428194.2014.974039. Epub 2015 Jul 23.

PMID:
25330445
24.

Assessment of TP53 functionality in chronic lymphocytic leukaemia by different assays; an ERIC-wide approach.

Te Raa GD, Malčiková J, Mraz M, Trbusek M, Le Garff-Tavernier M, Merle-Béral H, Greil R, Merkel O, Pospíšilová S, Lin K, Pettitt AR, Stankovic T, van Oers MH, Eldering E, Stilgenbauer S, Zenz T, Kater AP; European Research Initiative on CLL (ERIC).

Br J Haematol. 2014 Nov;167(4):565-9. doi: 10.1111/bjh.13006. Epub 2014 Jun 30. No abstract available.

PMID:
24975017
25.

Activated innate lymphoid cells are associated with a reduced susceptibility to graft-versus-host disease.

Munneke JM, Björklund AT, Mjösberg JM, Garming-Legert K, Bernink JH, Blom B, Huisman C, van Oers MH, Spits H, Malmberg KJ, Hazenberg MD.

Blood. 2014 Jul 31;124(5):812-21. doi: 10.1182/blood-2013-11-536888. Epub 2014 May 22.

PMID:
24855210
26.

Frontline low-dose alemtuzumab with fludarabine and cyclophosphamide prolongs progression-free survival in high-risk CLL.

Geisler CH, van T' Veer MB, Jurlander J, Walewski J, Tjønnfjord G, Itälä Remes M, Kimby E, Kozak T, Polliack A, Wu KL, Wittebol S, Abrahamse-Testroote MC, Doorduijn J, Ghidey Alemayehu W, van Oers MH.

Blood. 2014 May 22;123(21):3255-62. doi: 10.1182/blood-2014-01-547737. Epub 2014 Apr 15.

PMID:
24735962
27.

Real-world costs of chronic lymphocytic leukaemia in the Netherlands.

Holtzer-Goor KM, Bouwmans-Frijters CA, Schaafsma MR, de Weerdt O, Joosten P, Posthuma EF, Wittebol S, Huijgens PC, Mattijssen EJ, Vreugdenhil G, Visser H, Peters WG, Erjavec Z, Wijermans PW, Daenen SM, van der Hem KG, van Oers MH, Groot CA.

Leuk Res. 2014 Jan;38(1):84-90. doi: 10.1016/j.leukres.2013.10.029. Epub 2013 Nov 8.

PMID:
24268350
28.

CMV-specific CD8+ T-cell function is not impaired in chronic lymphocytic leukemia.

te Raa GD, Pascutti MF, García-Vallejo JJ, Reinen E, Remmerswaal EB, ten Berge IJ, van Lier RA, Eldering E, van Oers MH, Tonino SH, Kater AP.

Blood. 2014 Jan 30;123(5):717-24. doi: 10.1182/blood-2013-08-518183. Epub 2013 Nov 18.

PMID:
24246502
29.

Dasatinib in combination with fludarabine in patients with refractory chronic lymphocytic leukemia: a multicenter phase 2 study.

Kater AP, Spiering M, Liu RD, Doreen Te Raa G, Slinger E, Tonino SH, Beckers MM, Daenen S, Doorduijn JK, Lankheet NA, Luijks DM, Eldering E, van Oers MH.

Leuk Res. 2014 Jan;38(1):34-41. doi: 10.1016/j.leukres.2013.10.004. Epub 2013 Oct 28.

PMID:
24238639
30.

Chronic lymphocytic leukemia disease progression is accelerated by APRIL-TACI interaction in the TCL1 transgenic mouse model.

Lascano V, Guadagnoli M, Schot JG, Luijks DM, Guikema JE, Cameron K, Hahne M, Pals S, Slinger E, Kipps TJ, van Oers MH, Eldering E, Medema JP, Kater AP.

Blood. 2013 Dec 5;122(24):3960-3. doi: 10.1182/blood-2013-04-497693. Epub 2013 Oct 7.

31.

IL-21 and CD40L signals from autologous T cells can induce antigen-independent proliferation of CLL cells.

Pascutti MF, Jak M, Tromp JM, Derks IA, Remmerswaal EB, Thijssen R, van Attekum MH, van Bochove GG, Luijks DM, Pals ST, van Lier RA, Kater AP, van Oers MH, Eldering E.

Blood. 2013 Oct 24;122(17):3010-9. doi: 10.1182/blood-2012-11-467670. Epub 2013 Sep 6.

PMID:
24014238
32.

CLL cells are resistant to smac mimetics because of an inability to form a ripoptosome complex.

Maas C, Tromp JM, van Laar J, Thijssen R, Elias JA, Malara A, Krippner-Heidenreich A, Silke J, van Oers MH, Eldering E.

Cell Death Dis. 2013 Aug 29;4:e782. doi: 10.1038/cddis.2013.305.

33.

A case of meningoencephalitis by the relapsing fever spirochaete Borrelia miyamotoi in Europe.

Hovius JW, de Wever B, Sohne M, Brouwer MC, Coumou J, Wagemakers A, Oei A, Knol H, Narasimhan S, Hodiamont CJ, Jahfari S, Pals ST, Horlings HM, Fikrig E, Sprong H, van Oers MH.

Lancet. 2013 Aug 17;382(9892):658. doi: 10.1016/S0140-6736(13)61644-X. No abstract available.

34.

Overview of available p53 function tests in relation to TP53 and ATM gene alterations and chemoresistance in chronic lymphocytic leukemia.

te Raa GD, Malcikova J, Pospisilova S, Trbusek M, Mraz M, Garff-Tavernier ML, Merle-Béral H, Lin K, Pettitt AR, Merkel O, Stankovic T, van Oers MH, Eldering E, Stilgenbauer S, Zenz T, Kater AP; European Research Initiative on CLL (ERIC).

Leuk Lymphoma. 2013 Aug;54(8):1849-53. doi: 10.3109/10428194.2013.796058. Epub 2013 Jun 24. Review.

PMID:
23614766
35.

The biological rationale and clinical efficacy of inhibition of signaling kinases in chronic lymphocytic leukemia.

de Weerdt I, Eldering E, van Oers MH, Kater AP.

Leuk Res. 2013 Jul;37(7):838-47. doi: 10.1016/j.leukres.2013.03.011. Epub 2013 Apr 15. Review.

PMID:
23597579
36.

C1-esterase inhibitor concentrate rescues erythrocytes from complement-mediated destruction in autoimmune hemolytic anemia.

Wouters D, Stephan F, Strengers P, de Haas M, Brouwer C, Hagenbeek A, van Oers MH, Zeerleder S.

Blood. 2013 Feb 14;121(7):1242-4. doi: 10.1182/blood-2012-11-467209. No abstract available.

PMID:
23411737
37.

Monoclonal B-cell lymphocytosis: recommendations from the Dutch Working Group on CLL for daily practice.

te Raa GD, van Oers MH, Kater AP; HOVON CLL working party.

Neth J Med. 2012 Jun;70(5):236-41. Review.

38.

CD20 antibodies: type II to tango?

van Oers MH.

Blood. 2012 May 31;119(22):5061-3. doi: 10.1182/blood-2012-04-420711. No abstract available.

PMID:
22653951
39.

Chronic lymphocytic leukemia specific T-cell subset alterations are clone-size dependent and not present in monoclonal B lymphocytosis.

te Raa GD, Tonino SH, Remmerswaal EB, van Houte AJ, Koene HR, van Oers MH, Kater AP.

Leuk Lymphoma. 2012 Nov;53(11):2321-5. doi: 10.3109/10428194.2012.698277. Epub 2012 Aug 25.

PMID:
22646856
40.

Expansion of effector T cells associated with decreased PD-1 expression in patients with indolent B cell lymphomas and chronic lymphocytic leukemia.

Tonino SH, van de Berg PJ, Yong SL, ten Berge IJ, Kersten MJ, van Lier RA, van Oers MH, Kater AP.

Leuk Lymphoma. 2012 Sep;53(9):1785-94. doi: 10.3109/10428194.2012.673224. Epub 2012 Apr 19.

PMID:
22397719
41.

Tipping the Noxa/Mcl-1 balance overcomes ABT-737 resistance in chronic lymphocytic leukemia.

Tromp JM, Geest CR, Breij EC, Elias JA, van Laar J, Luijks DM, Kater AP, Beaumont T, van Oers MH, Eldering E.

Clin Cancer Res. 2012 Jan 15;18(2):487-98. doi: 10.1158/1078-0432.CCR-11-1440. Epub 2011 Nov 29.

42.

Long-term follow-up of autologous hematopoietic stem cell transplantation for severe refractory Crohn's disease.

Hommes DW, Duijvestein M, Zelinkova Z, Stokkers PC, Ley MH, Stoker J, Voermans C, van Oers MH, Kersten MJ.

J Crohns Colitis. 2011 Dec;5(6):543-9. doi: 10.1016/j.crohns.2011.05.004. Epub 2011 Jun 12.

PMID:
22115372
43.

Intracerebral infiltration as the unique cause of the clinical presentation of chronic lymphocytic leukemia/small lymphocytic leukemia.

Tonino SH, Rijssenbeek AL, Oud ME, Pals ST, van Oers MH, Kater AP.

J Clin Oncol. 2011 Dec 1;29(34):e837-9. doi: 10.1200/JCO.2011.37.5055. Epub 2011 Oct 24. No abstract available.

PMID:
22025138
44.

Precursor T-lymphoblastic lymphoma presenting as primary renal lymphoma with acute renal failure.

Kwakernaak AJ, Hazenberg MD, Roelofs JJ, van Noesel CJ, van Oers MH, van Tellingen A.

NDT Plus. 2011 Oct;4(5):289-91. doi: 10.1093/ndtplus/sfr079. Epub 2011 Jul 22.

45.

CD40 stimulation sensitizes CLL cells to lysosomal cell death induction by type II anti-CD20 mAb GA101.

Jak M, van Bochove GG, Reits EA, Kallemeijn WW, Tromp JM, Umana P, Klein C, van Lier RA, van Oers MH, Eldering E.

Blood. 2011 Nov 10;118(19):5178-88. doi: 10.1182/blood-2011-01-331702. Epub 2011 Sep 26.

PMID:
21948297
46.

Treatment strategies in advanced stage follicular lymphoma.

van Oers MH, Kersten MJ.

Best Pract Res Clin Haematol. 2011 Jun;24(2):187-201. doi: 10.1016/j.beha.2011.03.003. Epub 2011 May 8. Review.

PMID:
21658618
47.

Postoperative complications associated with transfusion of platelets and plasma in cardiac surgery.

Bilgin YM, van de Watering LM, Versteegh MI, van Oers MH, Vamvakas EC, Brand A.

Transfusion. 2011 Dec;51(12):2603-10. doi: 10.1111/j.1537-2995.2011.03200.x. Epub 2011 Jun 3.

PMID:
21645007
48.

CD40 stimulation sensitizes CLL cells to rituximab-induced cell death.

Jak M, van Bochove GG, van Lier RA, Eldering E, van Oers MH.

Leukemia. 2011 Jun;25(6):968-78. doi: 10.1038/leu.2011.39. Epub 2011 Mar 15.

PMID:
21403646
49.

ROS-mediated upregulation of Noxa overcomes chemoresistance in chronic lymphocytic leukemia.

Tonino SH, van Laar J, van Oers MH, Wang JY, Eldering E, Kater AP.

Oncogene. 2011 Feb 10;30(6):701-13. doi: 10.1038/onc.2010.441. Epub 2010 Oct 11.

50.

Dichotomy in NF-kappaB signaling and chemoresistance in immunoglobulin variable heavy-chain-mutated versus unmutated CLL cells upon CD40/TLR9 triggering.

Tromp JM, Tonino SH, Elias JA, Jaspers A, Luijks DM, Kater AP, van Lier RA, van Oers MH, Eldering E.

Oncogene. 2010 Sep 9;29(36):5071-82. doi: 10.1038/onc.2010.248. Epub 2010 Jun 28.

PMID:
20581863

Supplemental Content

Loading ...
Support Center